Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.
Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.
A retrospective comprehensive study looked at 94 patients, all who received the immune checkpoint inhibitor pembrolizumab for the treatment of their cancer, to determine how many experienced the side effect of thyroiditis.
In the study, the incidence of any thyroid abnormality was as high as 15%, says Delivanis. Of the 14 patients that experienced thyroid abnormality there were 7 cases of thyroiditis, 4 cases of new-onset or subclinical hypothyroidism, and three cases of recurrent hypothyroidism that required adjustments in treatment.
Radical Prostatectomy Shows Less Genitourinary Toxicity in Localized Prostate Cancer
April 30th 2025A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.
Read More
Neoadjuvant Mitomycin C Before TURBT for NMIBC: Safety and Potential Delayed Benefit
April 30th 2025A phase 3 trial showed neoadjuvant mitomycin C before TURBT in NMIBC patients was safe. While 12-month recurrence-free survival was similar to standard care, an 18-month trend suggested a possible delayed benefit.
Read More